News, views and contacts from the global Drugdevelopment industry
27 April 2017
Digital Magazine
Latest Companies

Pfanstiehl - Injectable and HPLE Carbohydrates for Protein Stabilisation and Optimisation

SYSTAG Systems Technik - Automation Systems for Small-Molecule Drug and API Development

Biovian - Contract Manufacturing Of Biopharmaceuticals

Sartorius - Biopharmaceutical Laboratory Equipment and Integrated Bioprocess Services

Pharmatest Services - Research Models to Evaluate Drug Candidate Efficacy

Press Releases

Malvern to Host Webinar on Using Multi-Setection size-exclusion chromatography to Evaluate Biosimilarity
Malvern has announced it will be hosting a new webinar presenting size-exclusion chromatography (SEC) data and discussing the impact of different formulations and external stress conditions on Monoclonal antibodies and biosimilar molecules.

Malvern to Host New Webinar on Difference Between Rheometers and Viscometers
Malvern has announced it will host a new webinar discussing the difference between rheometers and viscometer to help viewers decide which of the two is most suitable for their application.

Pharmatest to Host Seven Presentations at AACR in Washington, US
Pharmatest Services has announced it will attend the annual meeting of American Association for Cancer Research (AACR) in Washington, US.

Shin-Etsu Purchase Gamlen D Series for Formulation Studies
Provider of a wide range of cellulose ether excipients Shin-Etsu PFMD has purchased a Gamlen D series powder compaction analyser for a laboratory application in Wiesbaden, Germany.

Malvern March Webinars
Malvern is hosting two webinars this month: Differential scanning calorimetry (robust and powerful physical characterisation of therapeutic protein products) and Cement (composition, structure, and fineness - we are stronger together!).

White Papers

Determining Characterisations of Biopharmaceutical Stability with DSC
An important parameter in production, manufacturing, formulation, and long-term storage, protein stability has large effects on biopharmaceutical products and higher stability means for...

Benefits of Trehalose
Products such as monoclonal antibodies (mAb), fusion proteins, peptides, vaccines, antibody drug conjugulates (ADC) and stem cells benefit from the stabilising effects of...

ePAT Automated Lab Reactor Optimised for 24/7 Data Capture
Systag Systems presents ePAT, a cost-effective device for automation in the laboratory....

Gamlen Study: Breaking Anisotropic Rod-Shaped Particles
Gamlen presents a study conducted by V. Penkavova1, L. Kulaviak1, M.C. Ruzicka1, M. Puncochar, and P. Zamostny on the 'Beaking of Anisotropic Rod-Saped...

Reasons to Upgrade to a MicroCal PEAQ-DSC System
Differential Scanning Calorimetry (DSC) is a tool for protein stability characterisation in drug development. Its data is used to advance stable and developable proteins into the pipeline,...


March's top stories: Cancer Research UK's pancreatic cancer trials, Novartis' Cosentyx in psoriasis
Cancer Research UK invested £10m in the PRECISION Panc project, including a network of clinical trials for the treatment of pancreatic cancer, and Novartis reported positive results from the extension A2302E1 trial of Cosentyx to modify the course of psoriasis. Drugdevelopment-technology.com wraps up the key headlines from March.

February's top stories: Merck's Phase III HIV-1 trial results, NIH's Phase I AGS-v vaccine trial
Merck reported positive results from the Phase III trial of its non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine (MK-1439) for the treatment of patients with HIV-1 infection, and NIH's NIAID initiated a Phase I trial of vaccine AGS-v to prevent mosquito-transmitted diseases. Drugdevelopment-technology.com wraps up the key headlines from February.

January's top stories: TG Therapeutics' Phase II trial, antidepressant hip fracture risk
TG Therapeutics began its Phase II investigator initiated trial of TGR-1202 in combination with ibrutinib to treat Diffuse Large B-cell Lymphoma (DLBCL), and a study suggested that antidepressant usage increases the risk of hip fracture. Drugdevelopment-technology.com wraps-up the key headlines from January.

2016: The year's biggest Drug Development Technology stories
NIAID began a new HIV vaccine study in South Africa and Eli Lilly’s Phase III trial of Alzheimer disease drug failed. Drugdevelopment-technology wraps-up the key headlines from 2016.

November’s top stories: Wellcome’s clinical trial network, Eli Lilly’s Alzheimer disease drug trial
UK’s Wellcome recommended a clinical trial network for efficient drug development, and Eli Lilly’s Alzheimer disease drug trial failed to meet endpoints. Drugdevelopment-technology.com wraps up the key headlines from November.


Ingrezza (valbenazine) for the Treatment of Tardive Dyskinesia
Ingrezza (valbenazine) is first and only US Food and Drug Administration (FDA) approved vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with Tardive dyskinesia (TD).

Austedo (deutetrabenazine) for the Treatment of Chorea
Austedo™ (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT 2) inhibitor indicated for the treatment of chorea associated with Huntington’s disease (HD).

Zejula (niraparib) for the Treatment of Ovarian Cancer
Zejula™ (Niraparib) is a poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor approved for the treatment of adult patients with ovarian cancer.

Xadago (safinamide) for the Treatment of Parkinson’s Disease (PD)
Xadago® (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of Parkinson's disease.

Translarna (ataluren) for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
Translarna™ (ataluren) is a protein restoration therapy indicated for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The drug was developed by PTC Therapeutics.

Follow Us:   Facebook Facebook    Twitter Twitter   
Click here to unsubscribe from the newsletter | Privacy Policy
You are receiving this email because you are either a valued subscriber to Drug Development Technology or have signed up via a partner web site. Your email address has not been, and will not be, given to third parties.

www.drugdevelopment-technology.com is a product of Kable. Copyright 2017 Kable, a trading division of Kable Intelligence Limited.